Clinicians and patients may find recent studies relevant to decisions about lipid-lowering therapy to be perplexing. There are now, for the first time, 3 evidence-based options to modify atherosclerotic cardiovascular disease risk via lipid-lowering medications. With new information emerging, recent guidelines aging, and decisions needing to be made, this is an opportune time to review lipid-lowering therapy in the age of increasing evidence-based choice. The focus in this Viewpoint is on typical patients, not those with extreme phenotypes.
Krumholz HM. Treatment of Cholesterol in 2017. JAMA. 2017;318(5):417–418. doi:10.1001/jama.2017.6753